



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 73**

(48) Corrigendum issued on:  
**17.03.2021 Bulletin 2021/11**

(45) Date of publication and mention  
of the grant of the patent:  
**11.11.2020 Bulletin 2020/46**

(21) Application number: **16739870.0**

(22) Date of filing: **22.01.2016**

(51) Int Cl.:  
**A61K 47/50** <sup>(2017.01)</sup> **A61P 35/00** <sup>(2006.01)</sup>  
**C07K 16/30** <sup>(2006.01)</sup> **C07K 19/00** <sup>(2006.01)</sup>  
**C12N 9/80** <sup>(2006.01)</sup> **C12N 9/96** <sup>(2006.01)</sup>  
**A61K 39/395** <sup>(2006.01)</sup> **C07K 16/28** <sup>(2006.01)</sup>  
**A61K 47/68** <sup>(2017.01)</sup> **A61K 47/64** <sup>(2017.01)</sup>

(86) International application number:  
**PCT/IB2016/050342**

(87) International publication number:  
**WO 2016/116907 (28.07.2016 Gazette 2016/30)**

(54) **ANTIBODY-UREASE CONJUGATES FOR THERAPEUTIC PURPOSES**  
**ANTIKÖRPER-UREASE-KONJUGATE FÜR THERAPEUTISCHE ZWECKE**  
**CONJUGUÉS ANTICORPS-URÉASE POUR DES FINS THÉRAPEUTIQUES**

(84) Designated Contracting States:  
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB**  
**GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO**  
**PL PT RO RS SE SI SK SM TR**

(30) Priority: **23.01.2015 US 201562107210 P**

(43) Date of publication of application:  
**03.01.2018 Bulletin 2018/01**

(73) Proprietor: **Helix Biopharma Corp.**  
**Richmond Hill, ON L4B 3J9 (CA)**

(72) Inventors:  
• **CHAO, Heman**  
**Aurora, Ontario L4G 0E5 (CA)**  
• **WONG, Wah Yau**  
**Edmonton, Alberta T5T 5Z8 (CA)**  
• **TIAN, Baomin**  
**Edmonton, Alberta T6W 1N5 (CA)**  
• **GASPAR, Kimberly Jayne**  
**Saskatoon, Saskatchewan S7K 0J7 (CA)**  
• **KUMAR, Praveen**  
**Saskatoon, Saskatchewan S7T 0G1 (CA)**

(74) Representative: **Hutter, Anton et al**  
**Venner Shipley LLP**  
**5 Stirling House**  
**Stirling Road**  
**The Surrey Research Park**  
**Guildford GU2 7RF (GB)**

(56) References cited:  
**EP-A1- 0 824 019 WO-A1-97/15316**  
**WO-A1-2004/009112 WO-A1-2013/185215**  
**WO-A1-2014/165985 CA-A1- 2 130 072**  
**CA-A1- 2 492 472 CA-A1- 2 877 505**  
**CA-A1- 2 908 475 US-A- 4 762 707**

• **Heman Chao ET AL: "Development of an alkalizing antibody-enzyme conjugate for NSCLC treatment that is in Phase I clinical testing Preclinical Studies Abstract Background Starting Dose Derivations Acknowledgement", L-DOS47 PRESENTATION AT AACR 2013 ANNUAL MEETING, 5 April 2013 (2013-04-05), XP055285609, Retrieved from the Internet: URL: <http://www.helixbiopharma.com/wp-content/uploads/2014/02/Helix-BioPharma-AACR.pdf> [retrieved on 2016-07-04]**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- **HELIX BIOPHARMA:** "L-DOS47: Single domain antibody conjugated anticancer therapy", BIT'S 5TH ANNUAL INTERNATIONAL CONGRESS OF ANTIBODIES, , 1 January 2013 (2013-01-01), pages 1-35, XP009505019, Retrieved from the Internet:  
URL:<http://www.helixbiopharma.com/wp-content/uploads/2014/02/LDOS47-ICA-2013-HZ-.pdf>
- **CHAO H:** "DOS47 - Killing cancer by altering the tumor microenvironment", DRUG DELIVERY TECHNOLOGY, DRUG DELIVERY TECHNOLOGY, LLC, US, vol. 11, no. 1, 1 January 2011 (2011-01-01), pages 68-72, XP002763192, ISSN: 1537-2898
- **CHANDLER H M ET AL:** "An investigation of the use of urease-antibody conjugates in enzyme immunoassays", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 53, no. 2, 17 September 1982 (1982-09-17), pages 187-194, XP023900599, ISSN: 0022-1759, DOI: 10.1016/0022-1759(82)90140-5 [retrieved on 1982-09-17]
- **Sigma:** "ANTI-MOUSE IgG (WHOLE MOLECULE) UREASE CONJUGATE", , 6 January 2006 (2006-01-06), pages 1-1, XP055517511, Retrieved from the Internet:  
URL:<https://www.sigmaaldrich.com/content/dam/sigma-aldrich/docs/Sigma/Datasheet/8/u1004dat.pdf> [retrieved on 2018-10-22]
- **MEYERHOFF M E ET AL:** "Electrode-based enzyme immunoassays using urease conjugates", ANALYTICAL BIOCHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 95, no. 2, 1 June 1979 (1979-06-01), pages 483-493, XP024827776, ISSN: 0003-2697, DOI: 10.1016/0003-2697(79)90760-7 [retrieved on 1979-06-01]
- **AN-PING DENG ET AL:** "Application of a polyaniline based ammonium sensor for the amperometric immunoassay of a urease conjugated Tal 1 protein", ANALYTICA CHIMICA ACTA, vol. 461, no. 1, 1 June 2002 (2002-06-01), pages 49-55, XP055517531, AMSTERDAM, NL ISSN: 0003-2670, DOI: 10.1016/S0003-2670(02)00251-9
- **TIAN ET AL.:** 'Production and characterization of a camelid single domain antibody-urease enzyme conjugate for the treatment of cancer' BIOCONJUGATE CHEMISTRY vol. 26, no. 6, 17 June 2015, pages 1144 - 1155, XP055271801 DOI: 10.1021/ACS.BIOCONJCHEM.5B00237
- **CHAO ET AL.:** 'Development of an alkalizing antibody-enzyme conjugate for NSCLC treatment that is in Phase I clinical testing' L-DOS47 PRESENTATION AT AACR 2013 ANNUAL MEETING, [Online] 05 April 2013, pages 1 - 1, XP055285609 Retrieved from the Internet: <URL:[HTTP://WWW.HELIXBIOPHARMA.COM/WP-CONTENT/UPLOADS/2014/02/HELIX-BIOPHARMA-AACR.PDF](http://WWW.HELIXBIOPHARMA.COM/WP-CONTENT/UPLOADS/2014/02/HELIX-BIOPHARMA-AACR.PDF) >
- **HELIX BIOPHARMA:** 'L-DOS47: Single domain antibody conjugated anticancer therapy' BIT'S 5TH ANNUAL INTERNATIONAL CONGRESS OF ANTIBODIES, [Online] 2013, XP009505019 Retrieved from the Internet: <URL:[WWW.HELIXBIOPHARMA.COM/WP-CONTENT/UPLOADS/2014/02/LDOS47-ICA-2013-HZ-.PDF](http://WWW.HELIXBIOPHARMA.COM/WP-CONTENT/UPLOADS/2014/02/LDOS47-ICA-2013-HZ-.PDF)>
- **CHAO:** 'DOS47 - Killing cancer by altering the tumor microenvironment' DRUG DEVELOPMENT AND DELIVERY vol. 11, no. 1, 01 January 2011, pages 68 - 72, XP002763192
- **WONG ET AL.:** 'Urease-induced alkalization of extracellular pH and its antitumor activity in human breast and lung cancers' JOURNAL OF EXPERIMENTAL THERAPEUTICS AND ONCOLOGY vol. 5, no. 2, 01 January 2005, pages 93 - 99, XP009147420